Arrowhead Pharmaceuticals, Inc. (0HI3.L)
USD 14.63
(3.67%)
USD 14.63
(3.67%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -205 Million USD | -14.84% |
| 2022 | -178.5 Million USD | -19.77% |
| 2021 | -149.03 Million USD | -59.98% |
| 2020 | -93.15 Million USD | -252.24% |
| 2019 | 61.19 Million USD | 209.39% |
| 2018 | -55.93 Million USD | -51.2% |
| 2017 | -36.99 Million USD | 54.74% |
| 2016 | -81.74 Million USD | 14.83% |
| 2015 | -95.97 Million USD | -80.14% |
| 2014 | -53.27 Million USD | -116.66% |
| 2013 | -24.58 Million USD | -16.6% |
| 2012 | -21.08 Million USD | -114.53% |
| 2011 | -9.83 Million USD | -11.68% |
| 2010 | -8.8 Million USD | 55.38% |
| 2009 | -19.72 Million USD | 43.64% |
| 2008 | -35 Million USD | 7.76% |
| 2007 | -37.94 Million USD | -78.66% |
| 2006 | -21.24 Million USD | -126.86% |
| 2005 | -9.36 Million USD | -238.14% |
| 2004 | -2.76 Million USD | -2831.96% |
| 2003 | -94.43 Thousand USD | 93.33% |
| 2002 | -1.41 Million USD | -1232.72% |
| 2001 | -106.26 Thousand USD | 2.72% |
| 2000 | -109.23 Thousand USD | -94.31% |
| 1999 | -56.21 Thousand USD | -32.91% |
| 1998 | -42.29 Thousand USD | 73.33% |
| 1997 | -158.61 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -176.14 Million USD | -39.58% |
| 2024 Q1 | -136.54 Million USD | -26.05% |
| 2024 Q2 | -126.19 Million USD | 7.58% |
| 2023 Q1 | -42.13 Million USD | 49.74% |
| 2023 Q2 | 48.16 Million USD | 214.31% |
| 2023 Q4 | -108.33 Million USD | -5.48% |
| 2023 FY | -205 Million USD | -14.84% |
| 2023 Q3 | -102.7 Million USD | -313.23% |
| 2022 Q4 | -83.83 Million USD | -14.98% |
| 2022 Q2 | 41.55 Million USD | 165.62% |
| 2022 Q1 | -63.32 Million USD | 2.41% |
| 2022 FY | -178.5 Million USD | -19.77% |
| 2022 Q3 | -72.9 Million USD | -275.46% |
| 2021 Q4 | -64.88 Million USD | -103.6% |
| 2021 FY | -149.03 Million USD | -59.98% |
| 2021 Q1 | -24.05 Million USD | 52.01% |
| 2021 Q2 | -28.23 Million USD | -17.37% |
| 2021 Q3 | -31.86 Million USD | -12.88% |
| 2020 Q3 | -15.94 Million USD | 28.3% |
| 2020 Q4 | -50.11 Million USD | -214.31% |
| 2020 Q2 | -22.24 Million USD | -358.22% |
| 2020 FY | -93.15 Million USD | -252.24% |
| 2020 Q1 | -4.85 Million USD | -150.36% |
| 2019 Q1 | 10.94 Million USD | 198.0% |
| 2019 Q3 | 18.59 Million USD | -15.51% |
| 2019 Q4 | 9.63 Million USD | -48.17% |
| 2019 Q2 | 22.01 Million USD | 101.08% |
| 2019 FY | 61.19 Million USD | 209.39% |
| 2018 Q3 | -15.91 Million USD | -5.89% |
| 2018 FY | -55.93 Million USD | -51.2% |
| 2018 Q4 | -11.16 Million USD | 29.84% |
| 2018 Q2 | -15.03 Million USD | -8.84% |
| 2018 Q1 | -13.81 Million USD | -34.76% |
| 2017 Q1 | -14.9 Million USD | 31.63% |
| 2017 FY | -36.99 Million USD | 54.74% |
| 2017 Q2 | -6.12 Million USD | 58.87% |
| 2017 Q4 | -10.25 Million USD | -79.38% |
| 2017 Q3 | -5.71 Million USD | 6.78% |
| 2016 Q3 | -19.34 Million USD | 9.04% |
| 2016 Q2 | -21.26 Million USD | -9.95% |
| 2016 Q4 | -21.79 Million USD | -12.69% |
| 2016 FY | -81.74 Million USD | 14.83% |
| 2016 Q1 | -19.34 Million USD | 23.34% |
| 2015 Q4 | -25.22 Million USD | -57.75% |
| 2015 FY | -95.97 Million USD | -80.14% |
| 2015 Q3 | -15.99 Million USD | 46.03% |
| 2015 Q2 | -29.63 Million USD | -17.99% |
| 2015 Q1 | -25.11 Million USD | -12.35% |
| 2014 Q1 | -7 Million USD | 12.37% |
| 2014 Q4 | -22.35 Million USD | -76.02% |
| 2014 Q3 | -12.7 Million USD | -13.27% |
| 2014 Q2 | -11.21 Million USD | -59.96% |
| 2014 FY | -53.27 Million USD | -116.66% |
| 2013 Q1 | -4.81 Million USD | 10.57% |
| 2013 Q2 | -5.39 Million USD | -12.06% |
| 2013 Q3 | -6.38 Million USD | -18.54% |
| 2013 Q4 | -7.99 Million USD | -25.18% |
| 2013 FY | -24.58 Million USD | -16.6% |
| 2012 Q1 | -4.03 Million USD | -38.67% |
| 2012 FY | -21.08 Million USD | -114.53% |
| 2012 Q4 | -5.37 Million USD | 20.94% |
| 2012 Q3 | -6.8 Million USD | -39.73% |
| 2012 Q2 | -4.86 Million USD | -20.54% |
| 2011 FY | -9.83 Million USD | -11.68% |
| 2011 Q1 | -1 Million USD | 57.02% |
| 2011 Q2 | -1.81 Million USD | -79.49% |
| 2011 Q3 | -1.77 Million USD | 2.29% |
| 2011 Q4 | -2.91 Million USD | -64.54% |
| 2010 Q3 | -2.16 Million USD | -1.63% |
| 2010 Q4 | -2.34 Million USD | -8.51% |
| 2010 FY | -8.8 Million USD | 55.38% |
| 2010 Q1 | -2.16 Million USD | 38.52% |
| 2010 Q2 | -2.12 Million USD | 1.42% |
| 2009 FY | -19.72 Million USD | 43.64% |
| 2009 Q4 | -3.51 Million USD | -51.21% |
| 2009 Q1 | -8.67 Million USD | 24.95% |
| 2009 Q2 | -5.21 Million USD | 39.87% |
| 2009 Q3 | -2.32 Million USD | 55.45% |
| 2008 Q4 | -11.55 Million USD | -16.8% |
| 2008 Q3 | -9.89 Million USD | -39.93% |
| 2008 Q2 | -7.07 Million USD | -2.72% |
| 2008 Q1 | -6.88 Million USD | 40.86% |
| 2008 FY | -35 Million USD | 7.76% |
| 2007 Q2 | -8.43 Million USD | -88.58% |
| 2007 Q1 | -4.47 Million USD | 48.93% |
| 2007 FY | -37.94 Million USD | -78.66% |
| 2007 Q4 | -11.64 Million USD | 13.1% |
| 2007 Q3 | -13.39 Million USD | -58.8% |
| 2006 FY | -21.24 Million USD | -126.86% |
| 2006 Q3 | -4.48 Million USD | -13.63% |
| 2006 Q1 | -4.05 Million USD | -96.64% |
| 2006 Q2 | -3.94 Million USD | 2.65% |
| 2006 Q4 | -8.75 Million USD | -95.4% |
| 2005 Q3 | -3.35 Million USD | -66.21% |
| 2005 Q2 | -2.01 Million USD | -2.86% |
| 2005 Q1 | -1.96 Million USD | -31.03% |
| 2005 FY | -9.36 Million USD | -238.14% |
| 2005 Q4 | -2.06 Million USD | 38.59% |
| 2004 Q2 | -388.93 Thousand USD | -172.9% |
| 2004 Q4 | -1.49 Million USD | -151.35% |
| 2004 Q1 | -142.52 Thousand USD | -709.6% |
| 2004 FY | -2.76 Million USD | -2831.96% |
| 2004 Q3 | -596.01 Thousand USD | -53.24% |
| 2003 Q3 | -15.1 Thousand USD | 48.76% |
| 2003 Q1 | -32.26 Thousand USD | 97.55% |
| 2003 FY | -94.43 Thousand USD | 93.33% |
| 2003 Q4 | -17.6 Thousand USD | -16.58% |
| 2003 Q2 | -29.46 Thousand USD | 8.66% |
| 2002 Q1 | -25.74 Thousand USD | 13.79% |
| 2002 FY | -1.41 Million USD | -1232.72% |
| 2002 Q4 | -1.31 Million USD | -2599.29% |
| 2002 Q3 | -48.87 Thousand USD | -117.91% |
| 2002 Q2 | -22.42 Thousand USD | 12.89% |
| 2001 Q4 | -29.86 Thousand USD | -92.44% |
| 2001 FY | -106.26 Thousand USD | 2.72% |
| 2001 Q2 | -25.52 Thousand USD | 27.79% |
| 2001 Q1 | -35.35 Thousand USD | -27.84% |
| 2001 Q3 | -15.51 Thousand USD | 39.21% |
| 2000 Q1 | -32.91 Thousand USD | -229.15% |
| 2000 FY | -109.23 Thousand USD | -94.31% |
| 2000 Q4 | -27.65 Thousand USD | -19.37% |
| 2000 Q2 | -25.49 Thousand USD | 22.54% |
| 2000 Q3 | -23.16 Thousand USD | 9.13% |
| 1999 Q3 | -220 Thousand USD | -2100.0% |
| 1999 FY | -56.21 Thousand USD | -32.91% |
| 1999 Q2 | -10 Thousand USD | 50.0% |
| 1999 Q1 | -20 Thousand USD | 0.0% |
| 1999 Q4 | -10 Thousand USD | 95.45% |
| 1998 Q2 | -10 Thousand USD | 0.0% |
| 1998 FY | -42.29 Thousand USD | 73.33% |
| 1998 Q3 | -10 Thousand USD | 0.0% |
| 1998 Q4 | -20 Thousand USD | -100.0% |
| 1997 FY | -158.61 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | -365.808% |
| Codexis, Inc. | -68.06 Million USD | -201.168% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 19.433% |
| Organovo Holdings, Inc. | -15.08 Million USD | -1258.889% |